Evolution of the Average Target: Virbac

Evolution of the Average Target - Virbac

Evolution of the Target Price: Virbac

Evolution of the Target Price - Virbac

Changes in Analyst Recommendations: Virbac

255a4ff33aa96b0d8.cJMb4-MuTvbOiGrH8volmB669gUGJCYfmefWfrRZ79s.SKo217J6G6njxin_x5Bv_2nVjDReVUdY0dOTD8A_i-NG43nTuUQ6tITGGQ~9be05e46bf6bbfaa4fb6cd4ebc983c85
20/10 Virbac: A well-done Q3 validates underlying quality Alphavalue
20/10 Virbac stock little changed despite strong update and targets now expected at the top end of the range Zonebourse
20/08 Cancer vaccines finally garner the spotlight Alphavalue
21/07 Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 Alphavalue
14/07 Where would AI lead Pharma in the long run? Alphavalue
11/05 Virbac continues decline despite positive recommendation Zonebourse
17/04 Virbac: 2026 starts on strong footing Alphavalue
19/03 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
18/03 Virbac in the green following results and outlook Zonebourse
20/01 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
20/01 Stifel Raises Price Target on Virbac Zonebourse
20/01 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
17/25/17 Virbac: Q3 crushed doubts about execution ability Alphavalue
17/25/17 The day the Fed resumed its rate cuts Zonebourse
15/25/15 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
17/25/17 Virbac: A healthy Q2 impresses the markets Alphavalue
03/25/03 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
03/25/03 Virbac: Oddo BHF upgrades stock Zonebourse
17/25/17 Virbac: brokers' advice following quarterly results Zonebourse
16/25/16 Virbac: Stifel remains bullish after quarterly results Zonebourse
16/25/16 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
16/25/16 Virbac: Stifel still buying after Q1 results Zonebourse
17/25/17 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
17/25/17 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
17/25/17 Virbac: Stifel raises its recommendation Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+17.86%
+4.04%
+3.97%
-1.12%
-3%
+12.65%
-3.77%
+23.18%
-11.3%
+0.7%
Average +4.32%
Weighted average by Cap. +3.07%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
348.50EUR
Average target price
410.75EUR
Spread / Average Target
+17.86%
High Price Target
440.00EUR
Spread / Highest target
+26.26%
Low Price Target
360.00EUR
Spread / Lowest Target
+3.30%

Analyst Consensus Detail

Analyst consensus - Virbac

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Virbac
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Virbac